<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02755337</url>
  </required_header>
  <id_info>
    <org_study_id>Dr. Soetomo General Hospital</org_study_id>
    <nct_id>NCT02755337</nct_id>
  </id_info>
  <brief_title>The Evaluation of Lung Cancer Patient Treated With Epidermal Growth Factor Receptor Tyrosine Kinase</brief_title>
  <acronym>EVALUATE</acronym>
  <official_title>The Evaluation of Lung Cancer Patient Treated With Epidermal Growth Factor Receptor Tyrosine Kinase</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Soetomo General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Soetomo General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate Non-Small Cell Lung Cancer (NSCLC) patients clinical profile and the outcome
      after treatment with Gefitinib in Pulmonary Oncology Outpatient Clinic Dr. Soetomo General
      Hospital, Surabaya, Indonesia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective: To determine the efficacy of Gefitinib in NSCLC patient harboring a
      positive EGFR mutation.

      Secondary Objective: To evaluate the subjective response of NSCLC patients harboring a
      positive EGFR mutation who treated with Gefitinib.

      Safety Objective: To evaluate the safety and tolerability of Gefitinib in NSCLC patient
      harboring a positive EGFR mutation.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>PFS (Progression Free Survival)</measure>
    <time_frame>through study completion, in average of 1 year</time_frame>
    <description>Progression Free Survival (PFS) as defined by RECIST 1.1 or attending physician's clinical judgement of clinical progression state</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>through study completion, in average of 1 year</time_frame>
    <description>Overall Survival (OS) as defined by the date of death certificate given by the attending physician or by other government officials</description>
  </primary_outcome>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Non-Small-Cell Lung Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        NSCLC patients (adenocarcinoma and non-adenocarcinoma histology) who harbor a positive EGFR
        mutation and receive Gefitinib (Iressa) as treatment.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  NSCLC based on histopathologic examination

          -  Adenocarcinoma and/or nonadenocarcinoma based on histology examination

          -  Clinical stadium stage IIIB and IV

          -  Age 16-70 years old

          -  Received gefitinib as therapy

          -  At least completed 2 (two) data sets of RECIST 1.1 evaluations during the study period
             from January 2013 until July 2015

        Exclusion Criteria:

          -  Missing data of any variables of the treatment outcomes in the medical record
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laksmi Wulandari, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dr. Soetomo General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laksmi Wulandari, MD, PhD</last_name>
    <phone>+628123019591</phone>
    <email>laksmigts@yahoo.co.id</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anna Febriani, MD</last_name>
    <phone>+62818703492</phone>
    <email>annafebriani@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dr. Soetomo General Hospital</name>
      <address>
        <city>Surabaya</city>
        <state>East Java</state>
        <zip>60286</zip>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laksmi Wulandari, MD. PhD</last_name>
      <phone>+628123019591</phone>
      <email>laksmigts@yahoo.co.id</email>
    </contact>
    <investigator>
      <last_name>Laksmi Wulandari, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 25, 2016</study_first_submitted>
  <study_first_submitted_qc>April 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2016</study_first_posted>
  <last_update_submitted>April 27, 2016</last_update_submitted>
  <last_update_submitted_qc>April 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dr. Soetomo General Hospital</investigator_affiliation>
    <investigator_full_name>Laksmi Wulandari, MD, PhD, FCCP</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>adenocarcinoma</keyword>
  <keyword>non-adenocarcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitogens</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

